Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,874,447

« Back to Dashboard

Which drugs does patent 5,874,447 protect, and when does it expire?


Patent 5,874,447 protects BRISDELLE and PEXEVA and is included in two NDAs. There has been one Paragraph IV challenge on Brisdelle.

This patent has thirty-eight patent family members in twenty-five countries.

Summary for Patent: 5,874,447

Title: 4-Phenylpiperidine compounds for treating depression
Abstract:The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: ##STR1## wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C.sub.1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, R.sup.1 represents hydrogen, trifluoro (C.sub.1-4) alkyl, alkyl or alkynyl, X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy, R.sup.2 represents: a C1-C10 alkyl group, a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.
Inventor(s): Benneker; Franciscus Bernardus Gemma (Nijmegan, NL), Van Dalen; Frans (Neunen, NL), Lemmens; Jacobus Maria (Mook, NL), Peters; Theodorus Hendricus Antonium (Arnhem, NL), Picha; Frantisek (Brno, CS)
Assignee: Synthon B. V. (Nijmegen, NL)
Application Number:08/872,023
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sebela Ireland Ltd
BRISDELLE
paroxetine mesylate
CAPSULE;ORAL204516-001Jun 28, 2013RXYesYes5,874,447► SubscribeY
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003RXYesNo5,874,447► Subscribe TREATMENT OF PANIC DISORDER
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003RXYesNo5,874,447► Subscribe OBSESSIVE COMPULSIVE DISORDER
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003RXYesNo5,874,447► Subscribe DEPRESSION
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-002Jul 3, 2003RXYesNo5,874,447► Subscribe TREATMENT OF PANIC DISORDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,874,447

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,900,327 4-phenylpiperidine compounds► Subscribe
7,598,271Crystalline paroxetine methane sulfonate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,874,447

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel133366► Subscribe
Hungary0003141► Subscribe
European Patent Office0994872► Subscribe
Estonia200200633► Subscribe
Estonia03970► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot